Sandoz Reaches $450 Million Settlement With 43 US States Over Antitrust Claims

Swiss generics manufacturer Sandoz announced Monday it will pay $450 million to settle long-standing litigation with 43 U.S. states and territories. The agreement, disclosed by the company, resolves allegations of anti-competitive practices within the U.S. generic drug market.

Terms of the Agreement

Under the terms of the settlement, Sandoz's U.S. subsidiary will distribute the payments over an extended period. The company specified the payment structure as follows:

• A primary payment of $400 million to be paid over seven years, starting from 2027.
• An additional sum of approximately $50 million to be paid to states that had settled earlier.

Sandoz explicitly stated that neither settlement contains an admission of wrongdoing by its U.S. unit. This allows the company to resolve the legal dispute without formally accepting liability for the alleged conduct.

Ad

Financial Impact and Context

Sandoz moved to reassure investors by confirming the settlement would not alter its financial projections. In its statement, the company said the agreements "do not affect full-year 2026 guidance or the Sandoz mid-term outlook."

The litigation stemmed from broad investigations into the generic pharmaceutical industry concerning alleged price-fixing and other anti-competitive behavior. This settlement resolves Sandoz's involvement with the participating states, removing a significant legal uncertainty for the company.